DRDO: Anti-COVID Drug 2-DG Launched to Treat Patients Suffering from Deadly Disease

NEW DELHI:

Anti-COVID Drug 2-DG Launched: The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The medicine comes in powder form and can be taken with water.

Defence Minister Rajnath Singh and Health Minister Harsh Vardhan released the first batch of the 2-DG, an anti-covid-19 therapeutic application of the drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy's Laboratories (DRL). [Also Read: DRDO Launches 1st Batch of Anti-Covid Drug 2DG (2-Deoxy-D-Glucose)]

Rajnath Singh handed over the anti-Covid drug to his cabinet colleague Harsh Vardhan who handed over it to Delhi All India Institute of Medical Sciences (AIIMS) director Randeep Guleria at an event here.

The Drugs Controller General of India (DCGI) granted emergency use nod for the drug last week. The drug could be a game-changer in the battle against pandemic as it helps in faster recovery of hospitalised patients and reduces oxygen dependence.

Clinical trial results have shown that the drug helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. (IANS)

Also Read: DCGI Approves Anti-COVID Drug Developed by DRDO for Emergency Use, How Will it Work?